H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 27.3 HKD -2.15% Market Closed
Market Cap: 23.8B HKD
Have any thoughts about
HUTCHMED (China) Ltd?
Write Note

HUTCHMED (China) Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HUTCHMED (China) Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
H
HUTCHMED (China) Ltd
HKEX:13
Other Long-Term Assets
$37.3m
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
62%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Other Long-Term Assets
HK$892m
CAGR 3-Years
38%
CAGR 5-Years
51%
CAGR 10-Years
11%
S
SSY Group Ltd
HKEX:2005
Other Long-Term Assets
HK$216.2m
CAGR 3-Years
33%
CAGR 5-Years
-6%
CAGR 10-Years
-6%
U
United Laboratories International Holdings Ltd
HKEX:3933
Other Long-Term Assets
ÂĄ87.8m
CAGR 3-Years
-9%
CAGR 5-Years
-22%
CAGR 10-Years
-13%
Sino Biopharmaceutical Ltd
HKEX:1177
Other Long-Term Assets
ÂĄ989.3m
CAGR 3-Years
-39%
CAGR 5-Years
-12%
CAGR 10-Years
6%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Other Long-Term Assets
HK$6.1B
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

HUTCHMED (China) Ltd
Glance View

Market Cap
23.8B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 1,759 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Intrinsic Value
21.49 HKD
Overvaluation 21%
Intrinsic Value
Price
H

See Also

What is HUTCHMED (China) Ltd's Other Long-Term Assets?
Other Long-Term Assets
37.3m USD

Based on the financial report for Jun 30, 2024, HUTCHMED (China) Ltd's Other Long-Term Assets amounts to 37.3m USD.

What is HUTCHMED (China) Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
62%

Over the last year, the Other Long-Term Assets growth was -6%. The average annual Other Long-Term Assets growth rates for HUTCHMED (China) Ltd have been 15% over the past three years , 21% over the past five years , and 62% over the past ten years .

Back to Top